# GAGE12B

## Overview
GAGE12B is a gene that encodes the G antigen 12B protein, a member of the GAGE family of cancer-testis antigens. These proteins are typically expressed in a restricted manner, primarily in the testis and various cancer types, making them of particular interest in oncology. The G antigen 12B protein is involved in chromatin dynamics and DNA repair processes, contributing to cellular resistance against apoptosis, particularly in the context of cancer treatment (Nin2023Biology). The gene's expression is regulated by epigenetic mechanisms, such as DNA methylation and histone modifications, which are pivotal for its activation in cancerous cells (Nin2023Biology). GAGE12B has been implicated in several cancers, including cervical, ovarian, and multiple myeloma, where its expression correlates with treatment resistance and poor prognostic outcomes (Fang2014Decitabine; Moreaux2010A). Additionally, its expression during human embryonic development suggests a potential role in testis differentiation (Mamsen2017Temporal).

## Function


## Clinical Significance
GAGE12B, a member of the GAGE family of cancer-testis antigens, is implicated in various cancers due to its altered expression. In cervical cancers, GAGE12B is associated with resistance to radiation-induced cell death. It enhances chromatin dynamics, facilitating DNA repair and protecting cells from apoptosis, which contributes to treatment resistance (Nin2023Biology). In multiple myeloma, GAGE12B is overexpressed in patient groups with poor prognostic outcomes, suggesting its role in defining high-risk categories (Moreaux2010A). 

In ovarian cancer, GAGE12B expression is upregulated in patients responding to decitabine treatment, indicating its potential as a biomarker for treatment response (Fang2014Decitabine). The gene is also upregulated in the peripheral areas of gliomas, which may relate to tumor progression (Alenda2021FFPE). 

GAGE12B's expression is regulated by epigenetic mechanisms, including DNA methylation and histone modifications, which are crucial for its activation in cancer cells (Nin2023Biology). Its expression pattern during human embryonic development suggests a role in testis differentiation, although its clinical significance in this context is not fully understood (Mamsen2017Temporal).


## References


[1. (Fang2014Decitabine) Fang Fang, Qingyao Zuo, Jay Pilrose, Yinu Wang, Changyu Shen, Meng Li, Phillip Wulfridge, Daniela Matei, and Kenneth P. Nephew. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget, 5(11):3579–3589, May 2014. URL: http://dx.doi.org/10.18632/oncotarget.1961, doi:10.18632/oncotarget.1961. This article has 38 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.1961)

[2. (Nin2023Biology) Dawn Sijin Nin and Lih-Wen Deng. Biology of cancer-testis antigens and their therapeutic implications in cancer. Cells, 12(6):926, March 2023. URL: http://dx.doi.org/10.3390/cells12060926, doi:10.3390/cells12060926. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12060926)

[3. (Mamsen2017Temporal) Linn S. Mamsen, Emil H. Ernst, Rehannah Borup, Agnete Larsen, Rasmus H. Olesen, Erik Ernst, Richard A. Anderson, Stine G. Kristensen, and Claus Y. Andersen. Temporal expression pattern of genes during the period of sex differentiation in human embryonic gonads. Scientific Reports, November 2017. URL: http://dx.doi.org/10.1038/s41598-017-15931-3, doi:10.1038/s41598-017-15931-3. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-15931-3)

[4. (Alenda2021FFPE) Cristina Alenda, Estefanía Rojas, and Luis M. Valor. Ffpe samples from cavitational ultrasonic surgical aspirates are suitable for rna profiling of gliomas. PLOS ONE, 16(7):e0255168, July 2021. URL: http://dx.doi.org/10.1371/journal.pone.0255168, doi:10.1371/journal.pone.0255168. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0255168)

[5. (Moreaux2010A) J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga, D. Hose, H. Goldschmidt, A. Jauch, T. Reme, M. Jourdan, M. Amiot, and C. Pellat-Deceunynck. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica, 96(4):574–582, December 2010. URL: http://dx.doi.org/10.3324/haematol.2010.033456, doi:10.3324/haematol.2010.033456. This article has 127 citations.](https://doi.org/10.3324/haematol.2010.033456)